SPC
GILD icon

Salient Private Client’s Gilead Sciences GILD Stock Holding History

Salient Private Client’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$4.84M Sell
62,755
-721
-1% -$54.5K 0.95% 33
2018
Q2 		$4.5M Sell
63,476
-3,969
-6% -$280K 0.76% 45
2018
Q1 		$5.08M Sell
67,445
-3,776
-5% -$300K 0.89% 41
2017
Q4 		$5.1M Buy
+71,221
New +$5.41M 1.05% 35

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Salient Private Client's GILD Position: Q3 2018 in Review

Salient Private Client reduced its Gilead Sciences (GILD) stake by 1.1% in Q3 2018, selling an estimated $54.5K and leaving 62,755 shares worth $4.84M. The position accounts for 0.95% of the portfolio, ranked #33.

Salient Private Client first reported a position in GILD in Q4 2017 and has held it in 4 quarters since. The position peaked at $5.1M in Q4 2017. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

  • Salient Private Client held 62,755 shares of Gilead Sciences worth $4.84M as of Q3 2018.
  • Salient Private Client sold 721 Gilead Sciences shares in Q3 2018, an estimated $54.5K.
  • Gilead Sciences made up 0.95% of Salient Private Client's portfolio in Q3 2018, its #33 holding.
  • Salient Private Client first reported a position in Gilead Sciences in Q4 2017 and has held it in 4 quarters since.
  • Salient Private Client's Gilead Sciences position peaked at $5.1M in Q4 2017.
  • 1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Salient Private Client's 13F filing for Q3 2018, filed 14 Nov 2018.